Enochian Biosciences Said On June 20 It Entered Into Purchase Agreement With Lincoln Park Capital Under Which It May Sell To Lincoln Park Up To $20M Of Shares Of Common Stock
$ENOB
Biotechnology: Pharmaceutical Preparations
Health Care
-8-K
-8-K
Save time and jump to the most important pieces.
8-K - RENOVARO INC. (0001527728) (Filer)
10-Q - RENOVARO INC. (0001527728) (Filer)
8-K - RENOVARO INC. (0001527728) (Filer)
LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Company's Senior Scientific Advisor. A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies. "We are incredibly excited to bring on Dr. Whitley as a Senior Scientific Advisor," said Enochian's CEO Dr. Mark Dybul. "Rich is not only a talented clinician, but also a well noted researcher whose experience and expertise will be instrumental in
The Board learned of the arrest of Dr. Serhat Gumrukçu after the Press Release by the Department of Justice on May 25, 2022;The Board has verified that the incident leading to the arrest occurred prior to the merger which created the Enochian of today, and is completely unrelated to the Company;The Board reviewed the important scientific discoveries of the inventor and the Company's rights with regards to those discoveries, which will be unchangedThe Board confirmed that Dr. Serhat Gumrukçu has had no formal role in the Company, and has no involvement with the Company's strong management, scientific team and collaborations with leaders in the field;Therefore, the Board strongly affirms its c
LOS ANGELES, April 20, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences (NASDAQ:ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, today is announcing the appointment of Dr. François Binette, Ph.D. as Executive Vice President for Research and Development. Dr. Binette brings over 25 years of Advanced Therapy and Regenerative Medicine product development expertise, most recently as Senior VP of Product Development at Lineage Cell Therapeutics where he led multiple innovative allogenic cell therapy programs from discovery to clinical stages and contributed to one of the largest non-cancer cell therapy corporate par
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer In silico detection for 12 additional cancers, including pancreaticMore than 2,600 proprietary biomarker panels Rapidly expanding to other cancers and diseases Innovative biotechnology firm with promising pancreatic cancer results projected to begin human studies for several challenging solid tumors by mid-2024Combination creates potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision, in silico drug discovery LOS ANGELES, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Renovaro BioSciences Inc. (NASDAQ:RENB) (NASDAQ:ENOB), an advanced, pre-clinical biot
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise that its 2023 Annual Stockholder Meeting (the "Annual Meeting"), which was scheduled to be held yesterday, June 22, 2023 at 12:00 p.m. Eastern Time, was convened and adjourned, without any business being conducted, due to the lack of the required quorum. As a result of the required quorum not being present, the Annual Meeting has been adjourned to 12:00 p.m. (Eastern Time) on Friday July 21, 2023 ("Adjourned Annual Meeting") to allow additional time for the Company's stockholders to vote on the
LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company's Pre-IND submission. If successful, that would allow clinical trials to begin by the first half of 2024. The Company's proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. The important confirmatory results from two humanized mouse models using our novel dendritic-cell based therapy, indepen
4 - RENOVARO INC. (0001527728) (Issuer)
3/A - RENOVARO INC. (0001527728) (Issuer)
4 - RENOVARO INC. (0001527728) (Issuer)
LOS ANGELES, June 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ:ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of Seraph Research Institute (SRI), presented data demonstrating daily reduction of Hepatitis B Virus (HBV) until it could no longer be detected by the 8th day. No toxicities to the liver or other tissues were identified. The findings were presented during the prestigious International Liver Conference, and presentations can be found (Link to presentations.) Enochian BioSciences holds the exclusive l
SC 13D/A - RENOVARO INC. (0001527728) (Subject)
SC 13D/A - RENOVARO INC. (0001527728) (Subject)
SC 13D/A - RENOVARO BIOSCIENCES INC. (0001527728) (Subject)
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancerIn silico detection for 12 additional cancers, including pancreaticMore than 2,600 proprietary biomarker panelsRapidly expanding to other cancers and diseasesInnovative biotechnology firm with promising pancreatic cancer results projected to begin human studies for several challenging solid tumors by mid-2024Combination creates potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision, in silico drug discovery
Gainers Mallinckrodt (AMEX:MNK) stock rose 41.7% to $1.53 during Monday's regular session. Trading volume for this security as of 13:31 EST is 14.8 million, which is 377.2% of its average full-day volume over the last 100 days. The company's market cap stands at $20.1 million. GoodRx Holdings (NASDAQ:GDRX) stock moved upwards by 34.8% to $9.1. As of 13:31 EST, this security is trading at a volume of 17.8 million shares, making up 1432.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.6 billion. SmileDirectClub (NASDAQ:SDC) stock rose 22.42% to $0.86. SmileDirectClub's stock is trading at a volume of 8.0 million shares as of 13:
Gainers Dynatronics (NASDAQ:DYNT) stock moved upwards by 17.7% to $0.92 during Wednesday's after-market session. The market value of their outstanding shares is at $3.7 million. Novan (NASDAQ:NOVN) shares rose 9.99% to $0.2. Trading volume for this security closed at 4.6 million, accounting for 680.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.6 million. Trinity Biotech (NASDAQ:TRIB) shares moved upwards by 8.79% to $1.11. The company's market cap stands at $42.4 million. 9 Meters Biopharma (NASDAQ:NMTR) shares moved upwards by 8.32% to $0.18. 9 Meters Biopharma's trading volume hit 901.9K shares by close, accounting for 3